Study wrapper · #283
Palmitoyl copper peptide and acetyl tyrosine complex enhances melanin production in both A375 and B16 cell lines.
Editor's note
A cell-culture study reporting that a combination agent, palmitoyl GHK-copper plus acetyl tyrosine (CP-AcT), increased melanin production in two melanoma cell lines (human A375 and mouse B16) at concentrations that did not reduce cell viability, alongside increases in tyrosinase activity and melanin-pathway gene and protein expression. This is in-vitro work only; human data are needed before any clinical conclusions can be drawn. Two framing points matter. First, the melanin effect is driven substantially by the acetyl tyrosine and copper delivery, not by GHK-Cu's better-known collagen and skin-repair biology, so it should not be read across to GHK-Cu's cosmetic uses. Second, the cells used are melanoma (cancer) lines; a compound that raises melanin output in melanoma cells in a dish is a mechanistic observation, not a benefit, and says nothing about safety. For GHK-Cu readers this sits at the edge of the peptide's story, a pigment-pathway experiment, not evidence for the peptide's marketed skin or wound applications.
Plain-language abstract
This laboratory study tested a mixture called CP-AcT, a fat-modified version of the copper peptide GHK-Cu combined with acetyl tyrosine, to see how it affected the production of melanin, the pigment that colours skin. The experiments used two melanoma (skin-cancer) cell lines, one human and one mouse. The researchers first checked which concentrations did not harm the cells, then measured melanin and the activity of tyrosinase, a key enzyme in making pigment. They also looked at several genes and three proteins involved in the melanin-making pathway. The mixture increased melanin production in both cell types, along with higher tyrosinase activity and greater activity of pigment-related genes and proteins. This is a cell-dish study in cancer cell lines, and the pigment-boosting effect owes a lot to the acetyl tyrosine and copper rather than to the peptide alone. No people were involved, and no benefit, side effect, or safety conclusion for humans can be drawn from it.